Abstract
The pharmacokinetics of grepafloxacin (GPFX) were studied in patients with impaired renal function. Patients were classified into 3 groups according to creatinine clearance (Ccr). 7 patients in group I (90 ≥Ccr>60), 10 patients in group II (60≥Ccr>30) and 7 patients in group III (30 Ccr).
The maximum plasma concentration achieved after a single oral administration of 200 mg of GPFX was 0.46μg/ml at 4.3 h in group I, 0.54μg/ml at 4.4 h in group II and 0.37μg/ml at 5.9 h in group M. The plasma elimination half-life was 11.2, 12.8 and 13.0 h, and AUC was 6.31, 7.51 and 5.96μg·h/ml, respectively. There were no significant differences in half-life and AUC between the 3 groups. The urinary recovery rates within 72 h of administration were 6.86%, 7.43% and 3.03% in groups I, II and III, respectively, indicating low values in group III. No drug-related adverse reactions were observed.
These results sμggested that GPFX is mainly excreted into the bile and that little dose adjustment is necessary even in patients with impaired renal function.
